Your browser doesn't support javascript.
loading
New graft manipulation strategies improve the outcome of mismatched stem cell transplantation in children with primary immunodeficiencies.
Elfeky, Reem; Shah, Ravi M; Unni, Mohamed N M; Ottaviano, Giorgio; Rao, Kanchan; Chiesa, Robert; Amrolia, Persis; Worth, Austen; Flood, Terry; Abinun, Mario; Hambleton, Sophie; Cant, Andrew J; Gilmour, Kimberly; Adams, Stuart; Ahsan, Gul; Barge, Dawn; Gennery, Andrew R; Qasim, Waseem; Slatter, Mary; Veys, Paul.
  • Elfeky R; Molecular and Cellular Immunology Unit, University College London (UCL) Great Ormond Street Institute of Child Health, London, United Kingdom; Department of Paediatric Allergy and Immunology, Ain Shams University, Cairo, Egypt. Electronic address: r.elfeky@ucl.ac.uk.
  • Shah RM; Blood and Bone Marrow Transplant Unit, Great Ormond Street Hospital, London, United Kingdom; Department of Paediatric Oncology and BMT, Alberta Children's Hospital, Calgary, Alberta, Canada.
  • Unni MNM; Host Defence Unit, Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom.
  • Ottaviano G; Department of Paediatrics, Fondazione MBBM University of Milan-Bicocca, Monza, Italy.
  • Rao K; Blood and Bone Marrow Transplant Unit, Great Ormond Street Hospital, London, United Kingdom.
  • Chiesa R; Blood and Bone Marrow Transplant Unit, Great Ormond Street Hospital, London, United Kingdom.
  • Amrolia P; Molecular and Cellular Immunology Unit, University College London (UCL) Great Ormond Street Institute of Child Health, London, United Kingdom; Blood and Bone Marrow Transplant Unit, Great Ormond Street Hospital, London, United Kingdom.
  • Worth A; Blood and Bone Marrow Transplant Unit, Great Ormond Street Hospital, London, United Kingdom.
  • Flood T; Host Defence Unit, Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom.
  • Abinun M; Host Defence Unit, Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom.
  • Hambleton S; Host Defence Unit, Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom.
  • Cant AJ; Host Defence Unit, Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom.
  • Gilmour K; Blood and Bone Marrow Transplant Unit, Great Ormond Street Hospital, London, United Kingdom.
  • Adams S; Blood and Bone Marrow Transplant Unit, Great Ormond Street Hospital, London, United Kingdom.
  • Ahsan G; Blood and Bone Marrow Transplant Unit, Great Ormond Street Hospital, London, United Kingdom.
  • Barge D; Host Defence Unit, Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom.
  • Gennery AR; Host Defence Unit, Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom.
  • Qasim W; Molecular and Cellular Immunology Unit, University College London (UCL) Great Ormond Street Institute of Child Health, London, United Kingdom.
  • Slatter M; Host Defence Unit, Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom.
  • Veys P; Molecular and Cellular Immunology Unit, University College London (UCL) Great Ormond Street Institute of Child Health, London, United Kingdom; Blood and Bone Marrow Transplant Unit, Great Ormond Street Hospital, London, United Kingdom.
J Allergy Clin Immunol ; 144(1): 280-293, 2019 07.
Article en En | MEDLINE | ID: mdl-30731121
ABSTRACT

BACKGROUND:

Mismatched stem cell transplantation is associated with a high risk of graft loss, graft-versus-host disease (GvHD), and transplant-related mortality. Alternative graft manipulation strategies have been used over the last 11 years to reduce these risks.

OBJECTIVE:

We investigated the outcome of using different graft manipulation strategies among children with primary immunodeficiencies.

METHODS:

Between 2006 and 2017, 147 patients with primary immunodeficiencies received 155 mismatched grafts 30 T-cell receptor (TCR) αß/CD19-depleted grafts, 43 cord blood (CB) grafts (72% with no serotherapy), 17 CD34+ selection with T-cell add-back grafts, and 65 unmanipulated grafts.

RESULTS:

The estimated 8-year survival of the entire cohort was 79%, transplant-related mortality was 21.7%, and the graft failure rate was 6.7%. Posttransplantation viral reactivation, grade II to IV acute graft-versus-host disease (aGvHD), and chronic graft-versus-host disease (cGvHD) complicated 49.6%, 35%, and 15% of transplantations, respectively. Use of TCRαß/CD19 depletion was associated with a significantly lower incidence of grade II to IV aGvHD (11.5%) and cGvHD (0%), although with a greater incidence of viral reactivation (70%) in comparison with other grafts. T-cell immune reconstitution was robust among CB transplants, although with a high incidence (56.7%) of grade II to IV aGvHD. Stable full donor engraftment was significantly greater at 80% among TCRαß+/CD19+-depleted and CB transplants versus 40% to 60% among the other groups.

CONCLUSIONS:

Rapidly accessible CB and haploidentical grafts are suitable alternatives for patients with no HLA-matched donor. Cord transplantation without serotherapy and TCRαß+/CD19+-depleted grafts produced comparable survival rates of around 80%, although with a high rate of aGvHD with the former and a high risk of viral reactivation with the latter that need to be addressed.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre / Enfermedades de Inmunodeficiencia Primaria Tipo de estudio: Etiology_studies Límite: Adolescent / Child / Child, preschool / Humans / Infant Idioma: En Año: 2019 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre / Enfermedades de Inmunodeficiencia Primaria Tipo de estudio: Etiology_studies Límite: Adolescent / Child / Child, preschool / Humans / Infant Idioma: En Año: 2019 Tipo del documento: Article